Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunotherapy
gene therapy genetically engineered cell |
| gptkbp:administeredBy |
gptkb:hospital
infusion specialized treatment center |
| gptkbp:alternativeName |
chimeric antigen receptor T cell
|
| gptkbp:approvedBy |
gptkb:FDA
2017 |
| gptkbp:approvedProduct |
gptkb:Carvykti
gptkb:Abecma gptkb:Tecartus gptkb:Kymriah gptkb:Yescarta gptkb:Breyanzi |
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
Phase II Phase III |
| gptkbp:developedBy |
genetic engineering
|
| gptkbp:hasComponent |
cell surface receptor
chimeric antigen receptor |
| https://www.w3.org/2000/01/rdf-schema#label |
CAR-T cell
|
| gptkbp:manufacturer |
patient's own T cells
|
| gptkbp:mechanismOfAction |
T cell activation
antigen recognition tumor cell lysis |
| gptkbp:requires |
genetic modification
quality control cell expansion leukapheresis lymphodepleting chemotherapy cryopreservation |
| gptkbp:riskFactor |
infection
hypogammaglobulinemia B cell aplasia |
| gptkbp:sideEffect |
neurotoxicity
cytokine release syndrome |
| gptkbp:studiedBy |
gptkb:Carl_June
gptkb:Michel_Sadelain autoimmune diseases solid tumors James N. Kochenderfer |
| gptkbp:target |
gptkb:CD19
gptkb:BCMA |
| gptkbp:treatment |
gptkb:mantle_cell_lymphoma
leukemia multiple myeloma diffuse large B-cell lymphoma follicular lymphoma |
| gptkbp:usedFor |
gptkb:cancer
hematologic malignancies |
| gptkbp:bfsParent |
gptkb:Killer_T_Cell
|
| gptkbp:bfsLayer |
5
|